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BACKGROUND: Among older adults with chronic kid-
ney disease (CKD), the comparative event rates of end-
stage renal disease (ESRD) and cause-specific death are
unknown.
OBJECTIVE: To compare the rates of ESRD, cardiovas-
cular and non-cardiovascular death and examine risk
factors for ESRD and all-cause mortality in Cardiovas-
cular Health Study (CHS) participants.
DESIGN: The CHS is a longitudinal cohort study of
community-dwelling adults aged 65 years and older.
PARTICIPANTS: 1,268 participants with an estimated
glomerular filtration rate (eGFR)<60 ml/min per
1.73 m
2 were followed until the time of first event
(ESRD, cardiovascular or non-cardiovascular death) or
until March 31, 2003.
MAIN MEASURES: The outcomes were ESRD, cardio-
vascular- and non-cardiovascular death. Rates of each
event were calculated, and a Cox Proportional Hazards
Model with a competing risk framework was used to
examine risk factors for ESRD as compared with death.
Predictors included age, gender, race, BMI, hyperten-
sion, diabetes, cardiovascular disease, heart failure,
tobacco use, eGFR, and total cholesterol.
KEY RESULTS: During 9.7 years of follow-up, 5% of
the cohort progressed to ESRD, and 61% of the cohort
died. The rate (per 100 person-years) was 0.5 for ESRD
and 6.8 for all-cause mortality (3.0 for cardiovascular
and 3.8 for non-cardiovascular mortality). In the com-
peting risk framework, lower eGFR, male gender,
African-American race, and higher BMI were associated
with an increased risk of ESRD.
CONCLUSIONS: Older adults with CKD are 13-fold
more likely to die from any cause than progress to
ESRD and are 6-fold more likely to die from cardiovas-
cular causes than develop ESRD.
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INTRODUCTION
In the United States, approximately one in three adults aged
65 years and older has chronic kidney disease (CKD), defined
as an eGFR<60 ml/min/1.73 m
2.
1 The majority of patients
with CKD do not progress to advanced stages of CKD because
death precedes the progression to end-stage renal disease
(ESRD),
2–4 even among patients with stage 4 CKD.
2 The risk of
death as compared to the risk of progression to ESRD may be
even higher in older patients with established CKD. To date,
studies have not specifically examined the comparative event
rates of kidney disease progression and death and determined
cause-specific death in older adults with established CKD.
Given the aging population,
5 the increasing prevalence of
CKD,
6 and the association of CKD with mortality,
7–9 under-
standing the clinical course and outcomes of older patients
with CKD is particularly important. For these reasons, we
examined the rates of ESRD, cardiovascular death (CV death),
and non-cardiovascular death (non-CV death) among older,
community-dwelling adults with moderate CKD, and we
determined the risk factors for progression from CKD to ESRD
and to death within a competing mortality risk framework.
METHODS
Participants. The Cardiovascular Heath Study (CHS) is a
prospective cohort study of community-dwelling persons
65 years of age and older designed to examine the epidemiology
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379of cardiovascular disease in older adults.
10 Between 1989 and
1990, the CHS recruited 5,201 Medicare-eligible participants from
Forsyth County, NC; Sacramento County, CA; Washington
County, MD; and Pittsburgh, PA.
11 Between 1992 and 1993, the
study recruited an additional 687 African-American participants.
CHS exclusion criteria included: institutionalization, inability to
provide informed consent, intention to move outside the
enrollment area within 3 years, use of a wheelchair within the
home, hospice care, or current chemotherapy or radiation for
cancer. At the time of study entry, extensive clinical data were
collected, including demographics, comorbid conditions,
biochemical data, and prevalent cardiovascular risk factors.
Participants were followed prospectively for cardiovascular events
(coronary artery disease, angina, congestive heart failure, stroke,
claudication), hospitalizations, and death by contact every
6m o n t h s .
12,13
To focus on the competing risks of death versus progression of
chronic kidney disease, we selected only those CHS participants
with a Modification of Diet in Renal Disease estimated glomerular
filtration rate (MDRD eGFR)<60 ml/min per 1.73 m
2 at baseline.
We further excluded participants if they had no baseline serum
creatinine measurement, prevalent ESRD requiring dialysis
therapy, or the cause of death could not be determined.
Outcomes. The primary outcomes of interest were ESRD
(defined as renal failure requiring renal replacement therapy)
and death; CV and non-CV death were secondary outcomes of
interest. To ascertain ESRD, the CHS cohort was linked to the
United States Renal Data System (USRDS) in 2005 (which
included data through March 31, 2003). In addition, a chart
review was performed to determine which CHS participants
met criteria for ESRD yet elected not to initiate dialysis, died
prior to receiving dialysis, or died prior to being enrolled in the
USRDS (e.g., initiated dialysis in the hospital and
subsequently withdrew dialysis). To identify these potential
CHS participants with ESRD who were not included in the
USRDS, charts of CHS participants were reviewed if the
participant had a procedure code for dialysis, discharge
diagnoses suggesting ESRD (e.g., renal failure, ESRD,
dialysis, or renal transplant), or the cause of death was renal
failure or failure to thrive. The charts were reviewed by one
investigator (LF), and potential cases were reviewed by the CHS
renal working group for concurrence.
CV death was defined as death due to cardiovascular,
cerebrovascular, atherosclerotic, or other vascular causes, and
was adjudicated by the CHS Events Subcommittee by a protocol
previously described in detail;
12 any death other than those
mentioned above was considered to be a non-CV death (e.g.,
cancer, dementia, pulmonary disease, or infection). In the CHS
study, death was determined by examining the Social Security
Death Index, Medicare claims data, local obituaries, and proxy
report. The cause of death was adjudicated by committee and
was based on review of medical records, death certificates,
autopsy reports, and descriptions by the proxy.
12,14
Participants were followed until the time of a first event or until
March 31, 2003, whichever came first.
Clinical Assessment and Measurement
All methods employed to asses the baseline characteristics of
the CHS cohort have been described elsewhere.
10,13,15 Demo-
graphic factors (age, gender, race), health behaviors (smoking),
co-existing illnesses (diabetes and hypertension), physical
exam findings (body mass index, systolic and diastolic blood
pressure), and laboratory values (total cholesterol, creatinine
and glucose) were ascertained at study entry. Diabetes was
defined by the use of a medication for diabetes or fasting
glucose level≥126 mg/dl. Hypertension was defined by systol-
ic pressure≥140 mmHg, diastolic pressure≥90 mm Hg, or the
use of antihypertensive medication(s). Prevalent coronary
heart disease (CHD) and prevalent congestive heart failure
(CHF) were defined using participant self-report, medical
record review, findings from the baseline physical examination,
and physician questionnaires.
13 Smoking was classified as
never, former, or current. Serum creatinine levels were mea-
sured using the Kodak Ektachem 700 Analyzer (Eastman
Kodak, Rochester, New York), a colorimetric method. Serum
creatinine was calibrated to the Cleveland Clinic Laboratory
using indirect calibration to the NHANES III data.
16 Creatinine-
based estimated GFR was calculated using the four-variable
Modification of Diet in Renal Disease (MDRD) equation, eGFR =
186.3 X (serum creatinine
-1.154) x (age
-0.203) x 1.212 (if black) X
0.742 (if female).
17
Statistical Analyses
Baseline characteristics by categories of MDRD eGFR (eGFR 45 to
<60 or<45 ml/min per 1.73 m
2) were described as means,
medians, or proportions. Unadjusted incidence rates for progres-
sion to ESRD and all-cause mortality (further categorized as CVor
non-CV related) were calculated per 100 person-years and also
described with respect to eGFR categories. A standard Cox
proportional hazards model analysis was not felt to be adequate
in the presence of competing risks because the cause-specific Cox
model treats competing risks of the event of interest as censored
observations, and the cause-specific hazard function does not
have a direct interpretation in terms of survival probability.
Therefore, a competing risk model was used to examine risk
factors for ESRD as compared with all-cause mortality. The
variables included in the competing risk model were age, gender,
race, BMI (<18.5, 18.5–24.9, 25–29.9, or ≥30), hypertension,
diabetes, cardiovascular disease, heart failure, tobacco use (never,
former, or current), eGFR, and total cholesterol (<200, 200–239, or
≥240 mg/dl). These variables were selected for inclusion in the
analysis because of their potential association with the risk of
ESRD and/or death and their availability in usual clinical practice
(thereby allowing for inference by clinicians). First, we computed
the cumulative incidence functio n( C I F )o fE S R Do v e rt i m e .A tt i m e
t, the CIF defined the probability of having ESRD by time t while
other participants had experienced a death (CV or non-CV). We
usedthemethodproposedby FineandGray, whichis basedonthe
proportional hazards model and models directly the effect of
covariates on the CIF for competing risk data.
18 Our model
distinguished between participants who were still alive and those
who had already failed from competing causes and allowed for
direct inference regarding the effects of covariates on the CIF. The
cumulative incidence of ESRD in the presence of CVand non-CV
mortality as competing risks was calculated similarly to the
Kaplan-Meier method, except in the competing risk method
participants who died were counted as events when calculating
the event-free survival and only participants who were truly alive
380 Dalrymple et al.: Competing Risk of ESRD and Death JGIMwere considered at risk for ESRD. Similarly, the cumulative
incidences of CV and non-CV mortality in the presence of ESRD
as a competing risk were calculated. All analyses were performed
using R 2.9.1 software (R Foundation for Statistical Computing
http://www.R-project.org) and SPSS statistical software (release
15.0.1.1, Chicago, IL).
Investigational Review Board approval for the data collection
procedures of CHS was obtained at each of the four clinical sites
and at the Data Coordinating Center (University of Washington).
RESULTS
CHS enrolled 5,888 participants,
11 and after exclusions, a
total of 1,268 subjects were included in the present study
(Fig. 1). The mean age of the cohort was 75 years, 46% of the
cohort was male, and the mean and median eGFR at study
entry were 51 and 53 ml/min per 1.73 m
2, respectively. At
study entry 77.7% of the cohort had stage 3a CKD (eGFR
45–59 ml/min per 1.73 m
2), 18.3% had stage 3b CKD (eGFR
30–44 ml/min per 1.73 m
2), 3.4% had stage 4 CKD (eGFR 15–
29 ml/min per 1.73 m
2), and 0.6% had stage 5 CKD not
requiring dialysis (eGFR<15 ml/min/1.73 m
2). Among the
participants, 33% had prevalent cardiovascular disease, 17%
had prevalent diabetes, and 69% had prevalent hypertension
(Table 1). The mean and median follow-up times were 8.9 and
9.7 years, respectively.
During follow-up there were a total of 768 deaths (61% of
cohort); of these, 338 were due to cardiovascular causes
(44%), and 430 (56%) were due to non-cardiovascular
causes. Sixty participants (4.7%) progressed to ESRD.
Figure 2 shows the cumulative incidence of events with
consideration of the competing risk. Of the 60 participants
with ESRD, 50 were identified through linkage to USRDS,
 5888 total CHS participants 
1278 with eGFR
< 60 ml/min/1.73 m
2 
6 excluded for prevalent ESRD 
4 excluded for unknown cause of death
80 excluded for missing serum creatinine 
4530 excluded for eGFR ≥ 60 ml/min/1.73 m
2
5201 participants enrolled in
initial CHS cohort* 
687 African-American participants recruited 
1992-1993  
3654 participants recruited 
from Medicare eligibility 
lists*
2009 letters returned or unable to contact 
716 deceased 
1845 ineligible or did not complete recruitment 
3635 refused participation
96 eligible but not recruited*
1547 eligible adults living in same household as
sampled individuals enrolled into study* 
11955 individuals sampled
from the Health Care
Financing Administration,s
Medicare eligibility lists* 
1268 included in analysis
*Recruitment of the initial Cardiovascular Health Study Cohort
11
Figure 1. Recruitment of Cardiovascular Health Study participants and selection of chronic kidney disease cohort.
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the rates per 100 person-years were 0.5 for ESRD and 6.8 for all-
cause mortality (3.0 for CV and 3.8 for non-CV mortality). The
rates of events were notably higher in those participants with an
eGFR<45 ml/min per 1.73 m
2 and in participants over 85 years
of age (Table 2).
In the multivariate Cox proportional hazards model with a
competing risk framework, factors associated with an increased
risk of progression to ESRD included male gender, African-
American race, a BMI≥25 (as compared with a BMI of 18.5-
24.9), and lower eGFR. In comparison, older age, male gender, a
BMI<18.5 (compared with a BMI of 18.5–24.9), hypertension,
diabetes, cardiovascular disease, heart failure, and former and
current tobacco use were each associated with an increased risk
of all-cause mortality (Table 3).
DISCUSSION
In our study of community-dwelling older persons with CKD,
we found participants were 13-fold more likely to die from any
cause than to progress to ESRD and 6-fold more likely to die
from cardiovascular-related causes. Among participants 76 to
85 years of age, the risk of death was more than 25-fold higher
than the risk of ESRD. Even among participants with more
advanced CKD (eGFR<45 ml/min per 1.73 m
2), death from
Table 1. Baseline Participant Characteristics
eGFR<60 ml/min/1.73 m
2 n=1,268 eGFR 45 to <60 ml/min/1.73 m
2 n=985 eGFR<45 ml/min/1.73 m
2 n=283
MDRD eGFR
a (ml/min/1.73 m
2) 51±9 55±4 36±8
Age (years) 75±6 74±6 77±7
Male 580 (46%) 440 (45%) 140 (50%)
African-American 140 (11%) 97 (10%) 43 (15%)
Body mass index (kg/m
2) 26.7±4.6 26.7±4.6 26.5±4.7
Diabetes 217 (17%) 157 (16%) 60 (21%)
Hypertension 877 (69%) 656 (67%) 221 (78%)
Prevalent cardiovascular disease 414 (33%) 297 (30%) 117 (41%)
Prevalent heart failure 104 (8%) 64 (7%) 40 (14%)
Systolic blood pressure (mmHg) 139±23 138±23 143±25
Diastolic blood pressure (mmHg) 71±12 71±12 71±13
Antihypertensive medications 792 (63%) 579 (59%) 213 (75%)
ACEI
b 149 (12%) 102 (10%) 47 (17%)
Smoking status
Former 537 (42%) 425 (43%) 112 (40%)
Current 128 (10%) 94 (10%) 34 (12%)
Total cholesterol (mg/dl) 212±42 212±41 212±46
Low density lipoprotein (mg/dl) 131±38 131±37 132±42
High density lipoprotein (mg/dl) 51±15 52±15 49±16
Data are presented as mean±SD or number (%) of subjects;
aModification of Diet in Renal Disease estimated glomerular filtration rate;
bangiotensin-
converting enzyme inhibitor
Figure 2. The cumulative incidence of end-stage renal disease (ESRD), cardiovascular death, and non-cardiovascular death during follow-up.
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Importantly, 61% of patients died, and only 5% of patients
developed ESRD during a median follow-up of more than 9
years.
Prior studies in disparate settings have compared risks for
ESRD versus death in patients with CKD. The overall findings
of our study are most similar to those from administrative
data-based cohorts of CKD patients receiving care either in a
Health Maintenance Organization (HMO)
2 or in Veterans
Affairs Medical Centers;
19 both of these prior studies found
older patients with moderate CKD were substantially more
likely to die than to reach ESRD. However, in these studies,
cause-specific death was not determined, and the mean follow-
up time ranged from only 3 to 4 years for patients with
moderate to severe CKD. On the opposite extreme from CHS
are the findings of Menon et al. from the MDRD Study
participants.
20 Among 1,666 randomized and nonrandomized
participants with predominantly stages 2 through 4 non-
diabetic CKD, participants were seven-fold more likely to
develop ESRD than to die prior to reaching ESRD. Even among
participants more than 65 years of age, the rate of ESRD was
double the rate of death. Differences between the MDRD cohort
and CHS likely explain the differences in findings, including
the younger age (mean age 50 years), the relatively low
prevalence of CVD (8%), the large proportion of participants
with polycystic kidney disease (23%), and the inclusion of
patients selected for a RCT in the MDRD Study. Our CHS
findings also differ from those of CKD patients referred for
nephrologist care, who have been observed to have either
higher or equal rates of ESRD as compared with rates of
Table 2. Rates of End-Stage Renal Disease, All-Cause, Cardiovascular and Non-Cardiovascular Mortality
N End-stage renal
disease
All-cause
mortality
Cardiovascular
mortality
Non-
cardiovascular mortality
Events Rate per 100
person-years
(95% CI)
Events Rate per 100
person-years
(95% CI)
Events Rate per 100
person-years
(95% CI)
Events Rate per 100
person-years
(95% CI)
MDRD eGFR
a
<60 1,268 60 0.5 (0.4, 0.7) 768 6.8 (6.4, 7.3) 338 3.0 (2.7, 3.3) 430 3.8 (3.5, 4.2)
45 to <60 985 26 0.3 (0.2, 0.4) 570 6.1 (5.6, 6.6) 245 2.6 (2.3, 3.0) 325 3.5 (3.1, 3.9)
<45 283 34 1.8 (1.2, 2.4) 198 10.3 (8.8, 11.7) 93 4.8 (3.8, 5.8) 105 5.4 (4.4, 6.5)
Age (years)
65–75 745 41 0.5 (0.4, 0.7) 355 4.8 (4.3, 5.3) 150 2.0 (1.7, 2.3) 205 2.8 (2.4, 3.1)
76–85 449 15 0.4 (0.2, 0.7) 346 10.2 (9.1, 11.3) 150 4.4 (3.7, 5.1) 196 5.8 (5.0, 6.6)
>85 74 4 1.1 (0.0, 2.1) 67 18.1 (13.7, 22.4) 38 10.2 (7.0, 13.5) 29 7.8 (5.0, 10.7)
aModification of Diet in Renal Disease estimated glomerular filtration rate in ml/min per 1.73 m
2
Table 3. Risk Factors for Progression to ESRD and All-Cause Mortality Within the Competing Risk Framework
ESRD All-cause mortality
HR (95% CI) p-value HR (95% CI) p-value
Age, per 5 year increase 0.64 (0.50, 0.83) <0.001 1.61 (1.51, 1.71) <0.001
Male 2.73 (1.54, 4.82) <0.001 1.31 (1.12, 1.54) <0.001
African American 2.13 (1.17, 3.90) 0.014 0.78 (0.58, 1.06) 0.108
BMI
a
<18.5 (No cases) - 2.37 (1.37, 4.10) 0.002
18.5–24.9 1.00 (Ref) 1.00 (Ref)
25–29.9 2.38 (1.14, 5.00) 0.021 0.98 (0.83, 1.16) 0.821
≥30 2.45 (1.11, 5.41) 0.027 0.88 (0.70, 1.11) 0.282
Hypertension 1.25 (0.88, 1.78) 0.211 1.25 (1.12, 1.39) <0.001
Diabetes mellitus 1.74 (0.95, 3.19) 0.072 1.57 (1.29, 1.92) <0.001
Cardiovascular disease 0.65 (0.36, 1.21) 0.173 1.38 (1.18, 1.62) <0.001
Heart failure 1.05 (0.46, 2.40) 0.798 1.77 (1.33, 2.35) <0.001
Smoking status
Never 1.00 (Ref) 1.00 (Ref)
Former 0.48 (0.26, 0.91) 0.024 1.36 (1.16, 1.61) <0.001
Current 0.53 (0.21, 1.33) 0.175 2.25 (1.75, 2.90) <0.001
eGFR
b , per 10 ml/min/1.73 m
2 decrease 3.25 (2.53, 4.18) <0.001 1.04 (0.95, 1.13) 0.460
Total cholesterol
<200 1.00 (Ref) 1.00 (Ref)
200–239 0.86 (0.45, 1.64) 0.650 0.90 (0.76, 1.06) 0.199
≥240 1.59 (0.84, 3.01) 0.156 0.94 (0.76, 1.16) 0.558
aBody mass index,
bModification of Diet in Renal Disease estimated glomerular filtration rate
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21,22 However, referred patients may differ from non-
referred patients in important ways including their per-
ceived health status and dialysis candidacy.
23 Our findings
allow clinicians to understand more generally the compet-
ing risks of death and ESRD in their older patients with
C K Da n de x p a n do nt h ep r e v i o u sf i n d i n g sa sw ed e t e r -
mined the specific rates of competing events and compared
risk factors for both ESRD and all-cause mortality within a
competing risk framework. In our study, the rate of CV-
related death approached the rate of all other causes of
death combined. Although we did not specifically examine
the different types of non-CV-related death, a previous CHS
s t u d yb yF r i e de ta l .
7 found that among participants with
C K D ,t h el e a d i n gc a u s eo fn o n - C Vd e a t hw a sc a n c e r ,a n d
the rate of cancer-related deaths was lower than the rate of
CV deaths (16.7 versus 28 per 1000 person-years).
In the competing risk framework, lower eGFR, male
gender, African-American race, and higher BMI were associ-
ated with an increased risk of progression to ESRD. Bi-
directional effects of age, tobacco use, and BMI were
observed. Older age and former tobacco use were associated
with a reduced risk of progression to ESRD and an increased
risk of death, whereas current tobacco use was associated
with a substantial increase in the risk of death, suggesting
that age and tobacco use were stronger predictors of death
than ESRD (i.e., a risk factor for renal function decline, such
as tobacco, was in fact a much stronger predictor of death in
t h ec o m p e t i n gr i s kf r a m e w o r k ) .H i g h e rB M Iw a sa s s o c i a t e d
with an increased risk of progression to ESRD but not death,
whereas a low BMI was associated with a significant increase
in the risk of death (similar to findings from previous CHS
studies
24,25). Although diabetes and hypertension were not
statistically significantly associated with an increased risk of
ESRD, the point estimates were consistent with an increased
risk of ESRD and were likely not statistically significant
because of the low number of patients reaching ESRD.
Interestingly, renal function was an important predictor of
ESRD but not all-cause mortality. Older age, cardiovascular
disease, heart failure, and current tobacco use, all of which
were more prevalent among participants with lower eGFR,
appeared to have a greater influence on the likelihood of
death as compared to progression to ESRD. In contrast, the
comparative risk of diabetes or hypertension on these out-
comes was less clear due to the overall similar effect sizes and
the small number of participants reaching ESRD. Our
findings suggest that older age, cardiovascular disease, heart
failure, and current tobacco use enhance the risk of death,
presumably through multiple mechanisms including an
increase in cardiovascular events, cancer, and infection,
resulting in death prior to progression of renal disease.
The strengths of our study include the methods used to
ascertain ESRD, the adjudication of CV death, the long-term
follow-up, and the implementation of the competing risk
framework for our statistical analysis. In our study, we
determined progression to ESRD through linkage to the
USRDS and chart review. We detected 17% of our ESRD
patients through chart review, underscoring the high degree
of under-ascertainment when only relying on the USRDS to
identify cases in this population. The use of sources other
than the USRDS to identify ESRD may be even more
important in older patients, a subgroup that may be more
likely to have dialysis withheld or withdrawn.
23 Importantly,
we used the CHS adjudicated cause of death, which allowed
us, in combination with findings from previous CHS studies,
to establish CV death as the leading cause of death in older
patients with CKD. In addition, we examined risk factors for
ESRD while accounting for the competing risk of death. This
s t a t i s t i c a la p p r o a c ha l l o w e du st ou n d e r s t a n dr i s kf a c t o r sf o r
progression to ESRD as compared to death. Alternative
approaches, such as censoring for death or combining ESRD
and death as the outcome of interest, would not have allowed
us to detect the bi-directional effects of age, BMI, and tobacco
use.
Our study had several limitations. One, the findings are
primarily applicable to community-dwelling older persons
with moderate CKD, and the outcomes may be significantly
different in institutionalized older persons. Second, we relied
on a single creatinine measurement to estimate the MDRD
eGFR, which may have resulted in misclassification of
subjects at study entry (with patients most likely being
misclassified as having CKD when they did not). However,
this type of misclassification would likely result in an
underestimate of events as opposed to an overestimate of
events (i.e., healthier subjects without CKD would have been
inaccurately classified as having CKD and would likely not
contribute events but would erroneously be included in the
CKD population). In addition, we did not have baseline
measures of urinary protein and therefore we could not
determine the effect of proteinuria on the risk of renal
progression or death. The majority of participants included
in our study had stage 3a CKD (78%), and few participants
h a da d v a n c e dC K D .T h e r e f o r e , our study did not include a
large number of participants at highest risk for progression to
ESRD, and our findings primarily apply to patients with stage
3a CKD. Finally, because only 5% of the cohort progressed to
ESRD, our ability to contrast the relative impact of a
predictor on the risk of ESRD as compared to death is
limited. Nonetheless, our cohort reflects the clinical course
of moderate CKD in older community-dwelling persons and
does identify important predictors of ESRD as compared with
all-cause mortality.
In summary, we found that older patients with moderate
CKD are substantially more likely to die than to reach ESRD,
and CV death is the single leading cause of death in this
population. These findings can aid clinicians in caring for and
counseling their older patients with CKD, and highlight the
importance of cardiovascular risk reduction and screening
for cardiovascular disease in this population.
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